Company intelligence / Profile preview
Lynk Pharmaceuticals
Hangzhou, Zhejiang, Chinalinkedin.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Lynk Pharmaceuticals has shown positive results in Phase 1b clinical trials for LNK01004, a skin-restricted JAK inhibitor for atopic dermatitis. The company anticipated initiating 3 Phase III studies in 2023 and has multiple programs in Phase I and II studies. LNK01004 demonstrated good safety with minimal systemic exposure and preliminary efficacy in exploratory clinical trials.
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Small moleculesJAK inhibitors
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Simcere PharmaceuticalsEQRx
Beyond the preview
Go deeper on Lynk Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lynk Pharmaceuticals.